Vertex Pharmaceuticals Incorporated (VRTX) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-03
(Q2 2026)
— full calendar
Earnings Reports
-
Vertex (VRTX) Q3 2025: Genavix Prescriptions Surge to 300,000 as Renal Pipeline Accelerates
June 16, 2026
-
Vertex Pharmaceuticals (VRTX) Q4 2025: Non-CF Portfolio Set to Exceed $500M, Anchoring Multi-Vertical Expansion
June 15, 2026
-
Vertex (VRTX) Q1 2026: Non-CF Portfolio Drives 25% of Growth as Renal Franchise Accelerates
May 05, 2026
-
Vertex (VRTX) Q2 2025: Genavix Prescriptions Top 110,000 as Commercial Diversification Accelerates
August 04, 2025
-
Vertex (VRTX) Q1 2025: Genavix Fills 25,000 Prescriptions as Commercial Diversification Accelerates
June 30, 2025